Major Depressive Disorder (DSM-V) – Landscape & Forecast – Disease Landscape & Forecast
The major depressive disorder (MDD) therapy market is crowded and highly genericized. The prominent use of drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line treatments contributes to the challenges that branded therapies face when entering this market. Brand-only drugs (e.g., Lundbeck / Takeda’s Trintellix / Brintellix, Lundbeck / Otsuka Pharmaceutical’s Rexulti / Rxulti) largely compete for use in treatment-refractory patients. Janssen’s Spravato, one of the most recent entrants into the depression market, offers a fast onset of therapeutic effect compared with the approved therapies, an attribute that fulfills a key unmet need; however, its use for treatment-resistant depression is constrained by multiple factors. Owing to the remaining unmet need, physicians will continue to look to emerging therapies—many of which offer novel mechanisms of action—as potential future treatments in this market.
QUESTIONS ANSWERED
- What is the size of the MDD therapy market in the G7 countries? What key events will influence the market over the next decade?
- What is the epidemiology of MDD in the G7 countries? What percentage of prevalent patients are diagnosed and drug-treated?
- What factors drive and constrain the use of branded antidepressants and atypical antipsychotics in MDD? Which branded therapy is expected to experience the most commercial success during the forecast period?
- What are the greatest areas of unmet need in the treatment of MDD, and how are emerging therapies expected to address these unmet needs?
CONTENT HIGHLIGHTS
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 34 country-specific interviews with thought-leading psychiatrists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Prevalence of MDD by country; diagnosed / drug-treated prevalence of MDD by country.
Forecast: 10-year, annualized, drug-level sales and patient share of key MDD therapies in 2022-2032, segmented by brands / generics.
Emerging therapies: Phase 3/PR: 8 drugs. Coverage of select early-phase products.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Major Depressive Disorder (DSM-V) - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for MDD
- Current treatments used for MDD
- Market events impacting the use of key current therapies in MDD
- Selective serotonin reuptake inhibitors
- Serotonin and norepinephrine reuptake inhibitors
- Dopaminergic / noradrenergic agents
- Atypical antipsychotics
- Mixed serotonin modulators
- Melatonin receptor agonists
- Tricyclic and tetracyclic antidepressants
- Monoamine oxidase inhibitors
- NMDA receptor modulators
- Nonpharmacological approaches
- Medical practice
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for MDD
- Estimated launch dates of key emerging therapies for the treatment of MDD
- GABA receptor modulators
- NMDA receptor modulators
- Serotonin-norepinephrine-dopamine triple reuptake inhibitors
- Orexin-2 receptor antagonists
- Atypical antipsychotics
- Psychedelics
- Kappa opioid receptor antagonists
- Early-phase pipeline analysis
- Key findings
- Access and Reimbursement Overview
- Methodology
- Appendix
Soumya Soni, M.Tech., Healthcare Research & Data Analyst, CNS and Ophthalmology. Ms. Soni has substantial experience in market research, competitive intelligence, promotional intelligence, and consulting. She has produced multiple competitive intelligence-based landscape reports in oncology and contributed to ad-hoc market research projects. She also has experience in post-conference report preparation for key medical conferences such as AACR, ESMO, SITC, and ASH. Ms. Soni holds a master’s degree in biotechnology from Jaypee Institute of Information Technology in Noida, India.
Himanshu Jain, M.S.(Pharm.), Senior Manager, CNS and Ophthalmology. He has authored content for psychiatry and ophthalmology indications, including forecasting markets for schizophrenia, depression, and dry eye disease. He has about 15 years of experience working in market research and consulting firms. He earned his master’s degree in Pharmacology & Toxicology from the National Institute of Pharmaceutical Education and Research and holds an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.